Shoulder Innovations Earnings Call Transcripts
Fiscal Year 2026
-
Shoulder arthroplasty is experiencing rapid growth, driven by innovative implants, AI-enabled planning, and a shift to outpatient procedures. New product launches and a robotics-as-a-service model are set to further differentiate offerings and support expansion beyond the U.S.
Fiscal Year 2025
-
Delivered 65% Q4 and 50% full-year revenue growth in 2025, driven by rapid surgeon adoption, new product launches, and strong ASC penetration. 2026 guidance targets 31–37% revenue growth, with stable margins and continued investment in innovation and commercial expansion.
-
Leadership leverages decades of experience to drive innovation in shoulder arthroplasty, with strong growth among high-volume surgeons and a focus on portable, ASC-friendly robotics. Financial outlook remains positive, with robust margins and plans to expand indications in 2026.
-
Operating in a $2.8B global market, the company leverages innovative implant and AI planning technologies to address key clinical challenges and ASC logistics. Recent regulatory wins and new product launches are set to expand market reach and improve margins.
-
Q3 revenue rose 58% year-over-year to $11.8M, with gross margin at 76.2% and strong cash reserves of $137M. Full-year guidance was raised to $45–$46M, reflecting robust adoption, new product launches, and continued expansion in high-volume surgeon users.
-
A leading player in the shoulder arthroplasty market reported 33% Q2 revenue growth, driven by innovative two-tray instrumentation, strong adoption, and a scalable commercial model. Recent IPO proceeds will fund commercial expansion and technology development, with continued focus on ASCs and enabling tech.